Skip to content

MitraClip® and Hemodynamic Effects of Relevant Iatrogenic Atrial Septum Defect Closure

MitraClip® and Hemodynamic Effects of Relevant Iatrogenic Atrial Septum Defect Closure - Evaluation of Morphologic and Functional Changes in a Randomized Setting

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03024268
Enrollment
80
Registered
2017-01-18
Start date
2016-01-31
Completion date
2021-12-31
Last updated
2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Septal Defects, Atrial, Mitral Valve Insufficiency

Brief summary

Aim of this prospective trial is to assess the hemodynamic effects of a MitraClip procedure caused iatrogenic arterial septal defect (iASD) and the functional changes after interventional iASD closure in a randomized setting.

Detailed description

Transcatheter mitral valve repair with the MitraClip system is a therapeutic alternative to surgery in selected high-risk patients. Clip placement requires interatrial transseptal puncture and meticulous manipulation of the steerable sheath. There is evidence that the persistence of a relevant iASD after MitraClip is associated with worse clinical outcomes and increased mortality. The purpose of this study is to investigate, if the interventional closure of an persistant hemodynamic relevant iASD 30 days after MitraClip implantation, has favorable effects on clinical outcome. Eligible patients, after obtaining written informed consent, are 1:1 randomized either in group A (interventional occlusion of iASD) or group B (best supportive care).

Interventions

DEVICEFigulla Flex Occluder (Occlutech)

Interventional closure of the iASD with an Figulla Flex Occluder (Occlutech)

Sponsors

Heart Center Leipzig - University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Informed consent * Previous MitraClip implantation * Persistent relevant iASD 30 days after MitraClip intervention

Exclusion criteria

* Unsuccessful MitraClip implantation * No relevant iASD 30 days after MitraClip intervention * Unstable angina in the previous 4 weeks * Valvular heart disease (aortic, tricuspid or pulmonary valve) planed for surgery or interventional therapy * Constrictive pericarditis / restrictive cardiomyopathies * Pericardial effusion planed for surgery or interventional therapy * Coagulation disorders * Malignant disease with a life expectance \< 12 months * Pregnancy * Participation in another study * iASD diameter \> 38 mm * Aortic minimum distance of the iASD \< 5 mm * Thrombus in left atrial appendage * Venous access impossible with a 24 French catheter system * Presence of an inferior vena cava filter

Design outcomes

Primary

MeasureTime frame
Change in Exercise tolerance: 6 minute walking testbaseline, 3 and 6 months

Secondary

MeasureTime frameDescription
Change in New York Heart Association Functional Classification assessmentbaseline, 3 and 6 monthsChanges in New York Heart Association Functional Classification
Changes in Echocardiography: bi ventricular function (2D and 3D)baseline, 3 and 6 months
Changes in Echocardiography: assessment of left atrium (2D and 3D)baseline, 3 and 6 months
Changes in Echocardiography: assessment of heart valvesbaseline, 3 and 6 months
Changes in Echocardiography: strain using speckle trackingbaseline, 3 and 6 months
Changes in Echocardiography: evaluation of iatrogenic ASD (2D and 3D)baseline, 3 and 6 months
Heart insufficiency bio markersbaseline and 6 months
Changes in Cardiac MRI: bi ventricular functionbaseline and 6 months
Changes in Cardiac MRI: left ventricular circumferential strainbaseline and 6 months
Changes in Cardiac MRI: flow measurements in main pulmonary artery and aortabaseline and 6 months
Evaluation of hospitalisation ratebaseline, 3, 6 and 12 monthsTelephone
Evaluation of mortalitybaseline, 3, 6 and 12 monthsTelephone
Combined endpoint (hospitalisation and mortality)baseline, 3, 6 and 12 monthsTelephone; Combined Endpoint of hospitalisation and mortality. For analysis the first event is counted regardless of severity.
Changes in quality of life in Minnesota Living with Heart Failure questionnairebaseline and 6 months
Changes in quality of life in Short Form - 36 questionnairebaseline and 6 months
Changes in Cardiac MRI: left ventricular longitudinal strainbaseline and 6 months

Other

MeasureTime frame
Acute changes in right and left ventricular pressures during interventionell ASD closureimmediately before and immediately after ASD closure

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026